Vivesto Past Earnings Performance
Past criteria checks 0/6
Vivesto's earnings have been declining at an average annual rate of -8.5%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 18.2% per year.
Key information
-8.5%
Earnings growth rate
10.6%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -18.2% |
| Return on equity | -61.7% |
| Net Margin | -1,766.0% |
| Next Earnings Update | 22 Aug 2024 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Vivesto makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 7 | -117 | 73 | 0 |
| 31 Dec 23 | 7 | -129 | 84 | 0 |
| 30 Sep 23 | 2 | -284 | 86 | 0 |
| 30 Jun 23 | 3 | -340 | 92 | 0 |
| 31 Mar 23 | 3 | -351 | 95 | 0 |
| 31 Dec 22 | 3 | -357 | 96 | 0 |
| 30 Sep 22 | 13 | -140 | 101 | 0 |
| 30 Jun 22 | 24 | -99 | 107 | 0 |
| 31 Mar 22 | 29 | -118 | 111 | 0 |
| 31 Dec 21 | 29 | -133 | 124 | 0 |
| 30 Sep 21 | -184 | -348 | 88 | 0 |
| 30 Jun 21 | -195 | -354 | 108 | 0 |
| 31 Mar 21 | -199 | -376 | 146 | 0 |
| 31 Dec 20 | 4 | -210 | 185 | 0 |
| 31 Oct 20 | 205 | -59 | 83 | 0 |
| 31 Jul 20 | 205 | -24 | 73 | 0 |
| 30 Apr 20 | 206 | -11 | 226 | 0 |
| 31 Jan 20 | 4 | -196 | 113 | 0 |
| 31 Oct 19 | 6 | -167 | 85 | 0 |
| 31 Jul 19 | 9 | -210 | 60 | 0 |
| 30 Apr 19 | 10 | -201 | 52 | 0 |
| 31 Jan 19 | 14 | -154 | 107 | 0 |
| 31 Oct 18 | 13 | -153 | 106 | 0 |
| 31 Jul 18 | 13 | -117 | 106 | 0 |
| 30 Apr 18 | 12 | -118 | 109 | 0 |
| 31 Jan 18 | 10 | -128 | 115 | 0 |
| 31 Oct 17 | 10 | -139 | 126 | 0 |
| 31 Jul 17 | 8 | -155 | 135 | 0 |
| 30 Apr 17 | 7 | -160 | 139 | 0 |
| 31 Jan 17 | 7 | -151 | 139 | 0 |
| 31 Oct 16 | 16 | -137 | 141 | 0 |
| 31 Jul 16 | 19 | -139 | 148 | 0 |
| 30 Apr 16 | 23 | -142 | 156 | 0 |
| 31 Jan 16 | 26 | -139 | 150 | 0 |
| 31 Oct 15 | 18 | -141 | 136 | 0 |
| 31 Jul 15 | 19 | -124 | 122 | 0 |
| 30 Apr 15 | 19 | -117 | 111 | 0 |
| 31 Jan 15 | 23 | -125 | 123 | 0 |
| 31 Oct 14 | 26 | -128 | 129 | 0 |
| 31 Jul 14 | 28 | -120 | 124 | 0 |
| 30 Apr 14 | 30 | -105 | 120 | 0 |
| 31 Jan 14 | 30 | -90 | 109 | 0 |
| 31 Oct 13 | 35 | -75 | 102 | 0 |
| 31 Jul 13 | 44 | -71 | 106 | 0 |
Quality Earnings: VIVES is currently unprofitable.
Growing Profit Margin: VIVES is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VIVES is unprofitable, and losses have increased over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare VIVES's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VIVES is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.9%).
Return on Equity
High ROE: VIVES has a negative Return on Equity (-61.66%), as it is currently unprofitable.